Regeneron Pharmaceuticals, Inc. $REGN Stake Cut by Hobbs Group Advisors LLC

Hobbs Group Advisors LLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 58.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 387 shares of the biopharmaceutical company’s stock after selling 545 shares during the quarter. Hobbs Group Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $203,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. Marietta Wealth Management LLC increased its position in Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after buying an additional 2,501 shares during the period. Sepio Capital LP increased its position in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after buying an additional 842 shares during the period. Founders Capital Management LLC increased its position in Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after buying an additional 538 shares during the period. PGGM Investments increased its position in Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after buying an additional 51,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after buying an additional 955 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on REGN shares. Sanford C. Bernstein increased their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price on the stock. UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $817.46.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $564.63 on Friday. The business’s 50-day moving average price is $573.95 and its 200 day moving average price is $564.51. The firm has a market cap of $59.84 billion, a P/E ratio of 14.23, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned $11.56 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.